Open access

Introductory Chapter: The Latest Knowledge

Written By

Gürkan Yardımcı, Server Serdaroğlu and Zekayi Kutlubay

Published: 06 September 2017

DOI: 10.5772/intechopen.69261

From the Edited Volume

Fundamentals of Sexually Transmitted Infections

Edited by Server Serdaroglu and Zekayi Kutlubay

Chapter metrics overview

1,581 Chapter Downloads

View Full Metrics

1. Introduction

Sexually transmitted infections (STIs) are caused by the transmission of more than 30 various bacteria, viruses, and parasites from one individual to another [1, 2]. Transmission can occur in different ways such as vaginal, anal, and oral sexual contact. Besides, they can also be transmitted from pregnant women to their fetus during pregnancy, during birth, through breast‐feeding, and by parenteral routes [1, 3].

STIs are still a serious public health problem despite efforts and precautions worldwide. According to the World Health Organization (WHO), it is estimated that more than 1 million new STIs occur everyday globally. In the United States (US), the total number of STIs is around 110 million per annum and 20 million of these cases are newly acquired [4]. In England, the rates of most of the STIs had rapidly increased from the late 1990s to 2012 and approximately 500,000 STI diagnoses are now made annually [5]. In 2012, more than 40,000 new cases of HIV/AIDS and more than 1.5 million cases of syphilis, gonorrhea, and hepatitis B were reported in China [6]. Approximately 250 million women are affected by gonorrhea, chlamydia, syphilis, or trichomoniasis per year [7].

1.1. Sexually transmitted bacterial infections

Chlamydia trachomatis infections are the most reported bacterial STI in the US [8]. In the United Kingdom (UK), although it is the most commonly diagnosed bacterial STI, it is thought that there are many chlamydial infections that cannot be diagnosed and treated. Therefore, its frequency is not clearly known, but there were approximately 240,000 diagnosis in 2012 [5]. A study reported that the overall prevalence of C. trachomatis infection was 11% with the highest prevalence observed in women between 16 and 20 years of age in Brazil [9]. Because most cases are asymptomatic, the detection of the infection depends on the screening [10].

Gonorrhea caused by Neisseria gonorrhoeae is usually characterized by urethritis in men and cervicitis in women [11]. N. gonorrhea is the second most common reported bacterial STI in the US [12]. More than 350,000 cases of gonorrhea were reported in the US in 2014.

Syphilis caused by Treponema pallidum is one of the bacterial STIs that has been known for centuries [13]. Globally, 12 million new cases are estimated annually. Most of the new cases are probably in Southern Asia and Sub‐Saharan Africa according to WHO [14]. The number of syphilis cases reported was about 46,000 in the US in 2010 [15].

Chancroid caused by Haemophilus ducreyi is more common in Africa, Asia, and Latin America. But recently, this infection is less common both in developed and in less‐developed countries. Due to diagnostic challenges, the exact frequency is not clearly known [16]. It is more common in men than in women and male circumcision is thought to reduce the risk of transmission of infection [17].

Donovanosis (also known as granuloma inguinale) caused by Klebsiella granulomatis (formerly known as Calymmatobacterium granulomatis) is less common disease that occurs with genital ulceration.

Lymphogranuloma venereum (LGV) is caused by C. trachomatis serotype L1, L2, and L3. Although the disease is endemic in East and West Africa, India, Southeast Asia, and the Caribbean, it is less common in Europe [18]. Also, LGV is traditionally described as “a sporadic disease” in North America, Europe, and Oceania, but highly prevalent in parts of Africa, Asia, and South America [19, 20].

1.2. Sexually transmitted viral infections

Human papilloma virus (HPV) is the most common STI in the US [21]. It is estimated that 14 million people are infected with HPV annually [22]. Although there are over 100 strains of HPV, only about 40 HPV strains that cause benign or malign lesions are detected on the surface of anogenital skin. HPV strains are divided into two categories: high‐risk strains and low‐risk strains. High‐risk strains, especially, HPV types 16 and 18, are responsible for malignant lesions such as cervical, penile, vulvar, vaginal, anal and oropharyngeal cancers, and premalignant lesions such as cervical dysplasia. Low‐risk strains are responsible for benign lesions such as anogenital warts, benign or low‐grade cellular changes, and recurrent respiratory papillomatosis (RRP) [21].

Genital herpes caused by the Herpes simplex virus (HSV) is the most common disease with genital ulceration worldwide. To date, it is estimated that about 50 million people are infected with HSV‐2 in the US and it is thought that there are over 750,000 new cases each year [23]. HSV is divided into two subtypes: HSV‐1 and HSV‐2. The main cause of genital herpes is HSV‐2; but in recent years, the frequency of genital diseases caused by HSV‐1 has increased due to increasingly common oral sex among adolescents and adults [24].

Human immunodeficiency virus (HIV)‐1 may transmit vertically and through blood in addition to sexual intercourse. About 78 million people have suffered from HIV and 39 million deaths have occurred since the beginning of this epidemic. While the global prevalence of HIV was 31 million in 2002, at the end of the next 10 years, this number exceeded 35 million [25].

While Hepatitis C virus (HCV) is transmitted primarily through blood exposure, it has globally emerged as a STD among HIV‐infected men that have sex with men for the last 20 years [26]. Moreover, illicit drug use, unprotected anal intercourse, potentially traumatic sexual practices such as first sexual experience and inappropriate and common use of sex toys are the other factors facilitating transmission [19].

1.3. Sexually transmitted parasitic infections

Trichomoniasis caused by Trichomonas vaginalis that is highly prevalent in the US affects 11 million people per year. Approximately 62% of this figure is women. Trichomoniasis is commonly asymptomatic (70–100% of male population and 35–85% of female population) and transmission between partners easily occurs [27, 28].


2. Management of STIs

While STIs continue to be a general public health problem worldwide, unfortunately, there is no globally established STI surveillance system. While passive STI surveillance is performed using reports from STI control programs and public health laboratories in some countries such as the US, Canada, and Australia, there are limited published STI surveillance reports from Middle East and Northern Africa and Sub‐Saharan Africa [29].

2.1. STI preventive counseling

In preventive counseling, interactive individual communication between health‐care provider and patient is very important. Providers should also inform to their patients about risk‐reduction strategies such as abstinence, condom use, limiting the number of sex partners, modifying sexual practices, and vaccination. High‐risk behaviors are defined by the US Preventive Services Task Force (USPSTF) as having multiple current partners, having a new partner, using condom inconsistently, having sex while under the influence of alcohol or drugs, or exchanging sex for money or drugs [30, 31].

2.2. Sexual abstinence

One of the most reliable ways to prevent STIs is to abstain from oral, vaginal, and anal sexual intercourse or to have a long‐term relationship with an uninfected partner. If any of the partners are being treated, couples should be informed that they should avoid sexual intercourse until the treatment is completed [30].

2.3. Vaccination

To prevent infectious diseases, vaccination seems to be the best strategy for long‐term protection [32]. Although preexposure vaccination is a very effective method for preventing transmission of STIs, vaccines have not yet been developed except for three viral diseases including HPV, hepatitis A, and hepatitis B [30, 31].

There are three different prophylactic HPV vaccines approved by the Food and Drug Administration (FDA): Cervarix (GlaxoSmithKline, NY), Gardasil (Merck&Co, Kenilworth, NJ), and Gardasil‐9 (Merck&Co) [25, 33]. The first generation HPV vaccines (bivalent Cervarix and quadrivalent Gardasil) are licensed in more than 100 countries since 2006. The second generation HPV vaccine (9vHPV vaccine) was licensed in the US in December 2014 [34]. Both males and females can be vaccinated with HPV vaccines according to Advisory Committee on Immunization Practices (ACIP). Vaccine can be applied from 9 years old. Furthermore, vaccination is recommended for females aged 13–21 years and for males 13–21 years who have not been vaccinated previously or who have not completed the three‐dose series. Any of the three different vaccines is recommended for females, although either Gardasil or Gardasil‐9 is recommended for males [22]. Quadrivalent HPV vaccine prevents both anal intraepithelial neoplasia (AIN) and anogenital warts in men [35].

Hepatitis B vaccine is recommended for everyone who has a risk of transmission of STIs [30, 36].

Hepatitis A vaccine, the same as hepatitis B vaccine, is recommended for men who have sex with men (MSM), injection drug users, and HIV‐infected persons who have not yet been infected with hepatitis A virus [30].

2.4. Using condom and other barrier methods

Male and female condoms play an important role both in preventing pregnancy and in reducing the risk of transmission of infections including HPV, HIV, HSV, gonorrhea, chlamydia, syphilis, hepatitis B, hepatitis C, and Trichomonas. For these purposes, condoms can be used alone or in combination with other contraceptive methods [7, 30]. Using male latex condoms recommended by Centers for Disease Control and Prevention (CDC) is quite important to protect HCV transmission, because there is no vaccine for hepatitis C infection [26]. Only one vaginally inserted condom is approved in the US. But, research on new vaginal female condom models like Origami female condom is still ongoing [7].

2.5. Male circumcision

Male circumcision may reduce the risk of transmission of HIV and some STIs in heterosexual men and is recommended for preventing heterosexually acquired HIV infection by the WHO and the Joint United Nations Program on HIV/AIDS (UNAIDS) [30]. Male circumcision also increases the tendency to genital discharge syndrome. With contradictory results, the efficacy of male circumcision in preventing STIs in the general population has not been clearly demonstrated [37].

2.6. Postexposure and preexposure prophylaxis

Postexposure prophylaxis (PEP) and preexposure prophylaxis (PrEP) of the uninfected partner are the other preventive strategies [7]. Genital hygiene methods (e.g., vaginal washing) after sexual exposure should not be recommended as preventive methods [30]. In addition, the reasons such as a clinician visit and medication initiation within 72 h after exposure limit the use of PEP. But on the contrary, oral PrEP approved by the FDA is an effective HIV prevention tool [7]. With the implementation of PrEP and other preventive strategies, it has been observed that there is a significant reduction in the number of newly diagnosed HIV cases that occur among MSM in the US each year [38, 39].

2.7. Partner management

The first step of partner management should be partner notification. Knowing the sex‐ and needle‐sharing partners of infected persons allow to communicate with them directly or through state and local health departments. Thus, health counseling can be provided to the partners at risk and may be encouraged for medical evaluation and treatment in health care services [30].


3. Risk factors for STIs

The distribution of STIs in the population varies depending on different factors including individuals, social, and structural factors [6]. All sexually active people including heterosexual persons, MSM, and women who have sex with women are at risk. Most of the STIs are transmitted more easily from a man to a woman than from a woman to a man. Adolescents and young adults are the age groups at greatest risk of acquiring of STIs due to some reasons such as having multiple sex partners, unprotected sexual intercourse, and substance use [3].

Younger age is a significant risk factor for STIs [6]. Young people, especially aged 15–24 years, have a large number of sexual partners than older adults and these young individuals do not have the habits of using regular condom during sexual intercourse. In women, STIs, mostly for chlamydia, genital warts, and gonorrhea, are usually seen from the age of 15, peak at 19 years, and begin to decline from the first year of the third decade [5].

Concurrent of HIV/STIs is significant risk factor for acquiring other STIs [5]. Some studies have shown that the transmission rates of HCV as a STI is very low among heterosexual couples. Similarly, the rate of sexually transmitted HCV infection in HIV‐negative MSM is low [40].

Socioeconomic status such as level of education, occupation, and number of sexual partners of the individual is the other risk factor for STIs. Individuals with low level of education, especially drug users, are at high risk for HIV. The frequency of HIV/STIs has increased in some occupations such as long‐distance truck drivers and sex workers. Due to possibility of multiple sex partners, STIs are frequently seen in people and regions with high‐income levels [5]. While more than half of four curable STIs including chlamydia, gonorrhea, trichomoniasis, and syphilis occurred in upper‐middle income countries, other remaining infections occurred in lower‐middle income countries with 23%, low‐income countries with 12%, and high‐income countries with 9%, respectively [2].

Some behaviors including having multiple sex partners, sexual intercourse without condom use, illicit drug use, sharing of injected equipment’s, and alcohol use are generally associated with a higher prevalence of HIV/STIs [5]. High‐risk behaviors such as serosorting and chemsex may increase the rate of sexually transmitted HCV [40].

3.1. Complications and morbidities of STIs

Most of the STIs are asymptomatic. For this reason, there may be unnoticed, undetected, and untreated cases and serious complications can be seen in these cases [1, 36]. Possible complications are shown in Table 1.

  • Female infertility

  • Genital neoplasia

  • Pelvic inflammatory disease (PID)

  • Epididymitis

  • Urethritis

  • Prostatitis

  • Ectopic pregnancy

  • Cervical cancer

  • Cardiovascular and neurological damage

  • Fetal and neonatal morbidity and mortality (stillbirths, neonatal death, preterm or low‐birth‐weight baby, blindness)

  • Aseptic meningitis

  • Preterm rupture of membranes during pregnancy

Table 1.

Possible complications caused by STIs [1, 5, 28, 4143].

3.2. Screening of STIs

As noted below, the screening of certain groups is urgently recommended:

  1. Everyone between the ages of 13 and 64 years should be tested at least once for HIV.

  2. Sexually active females up to 24 years should routinely be screened for chlamydia every year.

  3. Nonpregnant women at higher risk of infection should be screened for gonorrhea and syphilis.

  4. Pregnant women, regardless of risk, should be screened for chlamydia, hepatitis B, HIV, and syphilis; pregnant women at higher risk of infection should also be screened for gonorrhea and hepatitis C.

  5. Men should be screened for HIV, and men at higher risk should also be screened for syphilis.

  6. MSM should be screened at least annually for HIV and syphilis and undergo a test for urethral chlamydia and gonorrhea infection. Men who participate in receptive anal intercourse should be tested for rectal chlamydia and gonorrhea and, in those who participate in oral intercourse, for pharyngeal gonorrhea [31].


4. STIs in children

STIs can also be seen in children. As transmission may be in utero, it may occur during delivery or after contact with contaminated devices and infected persons. But it should always be kept in mind that there may be sexual abuse [44]. Victims of sexual abuse were reported as 1.8 per 1000 children in 2006 [45].

In asymptomatic prepubertal children, STIs screening for all organisms from all sites is not recommended by American Academy of Pediatrics (AAP) guidelines. However, the clinician should consider the following situations when deciding whether to screen or not:

  1. History of penetration or evidence of recent or healed penetrative injury to the genitals, anus, or oropharynx.

  2. Abuse by a stranger.

  3. Abuse by a perpetrator known to be infected with an STI or at high risk of STIs (intravenous drug users, MSM, or people with multiple sexual partners).

  4. Sibling or other relative in the household with an STI.

  5. Residence in an area with a high rate of STI in the community.

  6. Signs or symptoms of STIs.

  7. Already diagnosed with one STI (and therefore should be screened for other STIs) [45].

Child sexual assault (CSA) survivors may have a risky sexual life in their future. Therefore, HPV vaccination for CSA survivors aged 9–26 years for females and aged 9–21 years for males is recommended in accordance with ACIP [45].


5. Conclusion

At present, STIs are not fully under control with current strategies and continue to cause serious public health problems. From early ages, individuals, especially those at high risk, should be informed about STIs and the methods of prevention from these infections. Health care providers should communicate individually with infected individuals and their partners. Proper screening of high‐risk individuals is crucial for early detection and treatment. Considered the data in recent years, it seems likely that the addition of vaccines that are proven efficacious to national vaccination programs of all countries would be beneficial.


  1. 1. Wagenlehner FM, Brockmeyer NH, Discher T, Friese K, Wichelhaus TA. The presentation, diagnosis, and treatment of sexually transmitted infections. Deutsches Ärzteblatt International. 2016;113:11-22. DOI: 10.3238/arztebl.2016.0011
  2. 2. Newman L, Rowley J, Vander Hoorn S, Wijesooriya NS, Unemo M, Low N, et al. Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS One. 2015;10:e0143304. DOI: 10.1371/journal.pone.0143304
  3. 3. Eng TR, Butler WT, editors. Institute of medicine (us) committee on prevention and control of sexually transmitted diseases. The Hidden Epidemic: Confronting Sexually Transmitted Diseases: Summary. Washington (DC): National Academies Press (US); 1997
  4. 4. Lupfer C, Anand PK. Integrating inflammasome signaling in sexually transmitted infections. Trends in Immunology. 2016;37:703-714. DOI: 10.1016/
  5. 5. Hughes G, Field N. The epidemiology of sexually transmitted infections in the UK: Impact of behavior, services and interventions. Future Microbiology. 2015;10:35-51. DOI: 10.2217/fmb.14.110
  6. 6. Zhao Y, Luo T, Tucker JD, Wong WC. Risk factors of HIV and other sexually transmitted infections in China: A systematic review of reviews. PLoS One. 2015;10:e0140426. DOI: 10.1371/journal.pone.0140426
  7. 7. Seidman D, Hemmerling A, Smith‐McCune K. Emerging technologies to prevent pregnancy and sexually transmitted infections in women. Seminars in Reproductive Medicine. 2016;34:159-167. DOI: 10.1055/s‐0036‐1571436
  8. 8. Lane AB, Decker CF. Chlamydia trachomatis infections. Disease‐a‐month. 2016;62:269-273. DOI: 10.1016/j.disamonth.2016.03.010
  9. 9. Brasiliense DM, Borges Bdo N, Ferreira WA. Genotyping and prevalence of Chlamydia trachomatis infection among women in Belém, Pará, northern Brazil. The Journal of Infection in Developing Countries. 2016;10:134-137. DOI: 10.3855/jidc.6474
  10. 10. Geisler WM. Diagnosis and management of uncomplicated Chlamydia trachomatis infections in adolescents and adults: Summary of evidence reviewed for the 2015 centers for disease control and prevention sexually transmitted diseases treatment guidelines. Clinical Infectious Diseases. 2015;61:S774‐S784. DOI: 10.1093/cid/civ694
  11. 11. Morgan MK, Decker CF. Gonorrhea. Disease‐a‐month. 2016;62:260-268. DOI: 10.1016/j.disamonth.2016.03.009
  12. 12. Lancaster JW, Mahoney MV, Mandal S, Lawrence KR. Update on treatment options for gonococcal infections. Pharmacotherapy. 2015;35:856-868. DOI: 10.1002/phar.1627
  13. 13. Eickhoff CA, Decker CF. Syphilis. Disease‐a‐month. 2016;62:280-286. DOI: 10.1016/j.disamonth.2016.03.012
  14. 14. Herbert LJ, Middleton SI. An estimate of syphilis incidence in Eastern Europe. Journal of Global Health. 2012;2:010402. DOI: 10.7189/jogh.02.010402
  15. 15. Shockman S, Buescher LS, Stone SP. Syphilis in the United States. Clinics in Dermatology. 2014;32:213-218. DOI: 10.1016/j.clindermatol.2013.08.005
  16. 16. Copeland NK, Decker CF. Other sexually transmitted diseases chancroid and donovanosis. Disease‐a‐month. 2016;62:306-313. DOI: 10.1016/j.disamonth.2016.03.016
  17. 17. Lewis DA, Mitjà O. Haemophilus ducreyi: From sexually transmitted infection to skin ulcer pathogen. Current Opinion in Infectious Diseases. 2016;29:52-57. DOI: 10.1097/QCO.0000000000000226
  18. 18. Stary G, Stary A. Lymphogranuloma venereum outbreak in Europe. Journal der Deutschen Dermatologischen Gesellschaft. 2008;6:935-940. DOI: 10.1111/j.1610‐0387.2008.06742.x
  19. 19. Apers L, Crucitti T, Verbrugge R, Vandenbruaene M. Sexually transmitted infections: what’s new? Acta Clinica Belgica. 2012;67:154-159
  20. 20. Savage EJ, van de Laar MJ, Gallay A, van der Sande M, Hamouda O, Sasse A, et al. European surveillance of sexually transmitted infections (ESSTI) network. Lymphogranuloma venereum in Europe 2003-2008. Eurosurveill. 2009;14(48):19428
  21. 21. Hutter JN, Decker CF. Human papillomavirus infection. Disease‐a‐month. 2016;62:294-300. DOI: 10.1016/j.disamonth.2016.03.014
  22. 22. Park IU, Introcaso C, Dunne EF. Human papillomavirus and genital warts: A review of the evidence for the 2015 centers for disease control and prevention sexually transmitted diseases treatment guidelines. Clinical Infectious Diseases. 2015;61:S849‐S855. DOI: 10.1093/cid/civ813
  23. 23. Koren M, Decker CF. Genital herpes. Disease‐a‐month. 2016;62:287-293. DOI: 10.1016/j.disamonth.2016.03.013
  24. 24. Sauerbrei A. Optimal management of genital herpes: Current perspectives. Infection and Drug Resistance. 2016;9:129-141. DOI: 10.2147/IDR.S96164
  25. 25. Wahid B, Ali A, Idrees M, Rafique S. Immunotherapeutic strategies for sexually transmitted viral infections: HIV, HSV, and HPV. Cellular Immunology. 2016;310:1-13. DOI: 10.1016/j.cellimm.2016.08.001
  26. 26. Decker CF. Emerging sexually transmitted diseases: Hepatitis C, lymphogranuloma venereum (LGV), and Mycoplasma genitalium infections. Disease‐a‐month. 2016;62:314-318. DOI: 10.1016/j.disamonth.2016.03.017.
  27. 27. Meites E, Gaydos CA, Hobbs MM, Kissinger P, Nyirjesy P, Schwebke JR et al. A review of evidence‐based care of symptomatic trichomoniasis and asymptomatic trichomonas vaginalis infections. Clinical Infectious Diseases. 2015;61:S837-848. DOI: 10.1093/cid/civ738
  28. 28. Mielczarek E, Blaszkowska J. Trichomonas vaginalis: Pathogenicity and potential role in human reproductive failure. Infection. 2016;44:447-458. DOI: 10.1007/s15010‐015‐0860‐0
  29. 29. Mohammed H, Hughes G, Fenton KA. Surveillance systems for sexually transmitted infections: A global review. Current Opinion in Infectious Diseases. 2016;29:64-69. DOI: 10.1097/QCO.0000000000000235
  30. 30. Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recommendations and Reports. 2010;59:1-110
  31. 31. Fanfair RN, Workowski KA. Clinical update in sexually transmitted diseases‐2014. Cleveland Clinic Journal of Medicine. 2014;81:91-101. DOI: 10.3949/ccjm.81a.13090
  32. 32. Edwards JL, Jennings MP, Apicella MA, Seib KL. Is gonococcal disease preventable? The importance of understanding immunity and pathogenesis in vaccine development. Critical Reviews in Microbiology. 2016;42:928-941. DOI: 10.3109/1040841X.2015.1105782
  33. 33. Handler NS, Handler MZ, Majewski S, Schwartz RA. Human papillomavirus vaccine trials and tribulations: Vaccine efficacy. Journal of the American Academy of Dermatology. 2015;73:759-767. DOI: 10.1016/j.jaad.2015.05.041
  34. 34. Pitisuttithum P, Velicer C, Luxembourg A. 9‐Valent HPV vaccine for cancers, pre‐cancers and genital warts related to HPV. Expert Review of Vaccines. 2015;14:1405-1419. DOI: 10.1586/14760584.2015.1089174
  35. 35. Shum J, Kelsberg G, Safranek S. Clinical Inquiry: Does qHPV vaccine prevent anal intraepithelial neoplasia and condylomata in men? The Journal of Family Practice. 2015;64:581-583
  36. 36. Ooi C, Lewis D. Updating the management of sexually transmitted infections. Australian Prescriber. 2015;38:204-208.
  37. 37. Van Howe RS. Sexually transmitted infections and male circumcision: A systematic review and meta‐analysis. International Scholarly Research Notices: Urology. 2013;2013:109846. DOI: 10.1155/2013/109846
  38. 38. Scott HM, Klausner JD. Sexually transmitted infections and pre‐exposure prophylaxis: Challenges and opportunities among men who have sex with men in the US. AIDS Research and Therapy. 2016;13:5. DOI: 10.1186/s12981‐016‐0089‐8
  39. 39. Cairns G, McCormack S, Molina JM. The European preexposure prophylaxis revolution. Current Opinion in HIV and AIDS. 2016;11:74-79. DOI: 10.1097/COH.0000000000000223
  40. 40. Chan DP, Sun HY, Wong HT, Lee SS, Hung CC. Sexually acquired hepatitis C virus infection: A review. International Journal of Infectious Diseases. 2016;49:47-58. DOI: 10.1016/j.ijid.2016.05.030
  41. 41. Tsevat DG, Wiesenfeld HC, Parks C, Peipert JF. Sexually transmitted diseases and infertility. American Journal of Obstetrics & Gynecology. 2017;216:1-9. DOI: 10.1016/j.ajog.2016.08.008
  42. 42. Ortayli N, Ringheim K, Collins L, Sladden T. Sexually transmitted infections: progress and challenges since the 1994 international conference on population and development (ICPD). Contraception. 2014;90:S22‐S31. DOI: 10.1016/j.contraception.2014.06.024
  43. 43. Rompalo A. Preventing sexually transmitted infections: Back to basics. Journal of Clinical Investigation. 2011;121:4580-4583. DOI: 10.1172/JCI61592
  44. 44. Rogstad KE, Wilkinson D, Robinson A. Sexually transmitted infections in children as a marker of child sexual abuse and direction of future research. Current Opinion in Infectious Diseases. 2016;29:41-44. DOI: 10.1097/QCO.0000000000000233
  45. 45. Seña AC, Hsu KK, Kellogg N, Girardet R, Christian CW, Linden J, et al. Sexual assault and sexually transmitted infections in adults, adolescents, and children. Clinical Infectious Diseases. 2015;61:S856-864. DOI: 10.1093/cid/civ786

Written By

Gürkan Yardımcı, Server Serdaroğlu and Zekayi Kutlubay

Published: 06 September 2017